Table 2. Sensitivity analysis based on various criteria for vasospasm.
| outcome | No. patients | No.RCTs | statins | placebo | RR (95%CI) | I2 | P Value for Heterogeneity |
|---|---|---|---|---|---|---|---|
| All trials7,8,14,15,16,23 | 249 | 6 | 51 of 124 | 68 of 125 | 0.80 (0.54–1.17) | 49% | 0.08 |
| Trials with simvastatin-use7,14,15,16,23 | 169 | 5 | 34 of 84 | 43 of 85 | 0.81 (0.49–1.35) | 53% | 0.08 |
| Trials with pravastatin-use8 | 80 | 1 | 17 of 40 | 25 of 40 | 0.68 (0.44–1.05) | — | — |
| Full text trials7,8,14,15,16 | 228 | 5 | 50 of 113 | 64 of 115 | 0.84 (0.58–1.21) | 48% | 0.1 |
| Only TCD vasospasm* 7,14,15 | 110 | 3 | 30 of 54 | 33 of 56 | 0.95 (0.54–1.66) | 64% | 0.06 |
| Quality of trials withouthigh risk7,8,14,15,16 | 228 | 5 | 50 of 113 | 64 of 115 | 0.84 (0.58–1.21) | 48% | 0.1 |
| statins treatment for 14 days7,8,15,16 | 189 | 4 | 37 of 94 | 53 of 95 | 0.74 (0.49–1.12) | 42% | 0.16 |
*in RCT of Chou 2005, 10 patients in statins group and 13 patients in placebo group developed TCD vasospasm.
RCTs: randomized controlled trials; RR: risk ratio; TCD: transcranial doppler.